Literature DB >> 22831156

Counteracting inflammation: a promising therapy in cachexia.

Josep M Argiles1, Francisco J Lopez-Soriano, Silvia Busquets.   

Abstract

Disease progression in cancer is dependent on the complex interaction between the tumor and the host inflammatory response. Indeed, both the tumor and the patient produce cytokines that act on multiple target sites such as bone marrow, myocytes, hepatocytes, adipocytes, endothelial cells, and neurons, where they produce a complex cascade of biological responses leading to the wasting associated with cachexia. The cytokines that have been involved in this cachectic response are TNF-α, IL-1, IL-6, and interferon-gamma. Interestingly, these cytokines share the same metabolic effects, and their activities are closely interrelated. In many cases these cytokines exhibit synergic effects when administered together. Therefore, therapeutic strategies- either nutritional or pharmacological-have been based on either blocking their synthesis or their action.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22831156     DOI: 10.1615/critrevoncog.v17.i3.30

Source DB:  PubMed          Journal:  Crit Rev Oncog        ISSN: 0893-9675


  26 in total

1.  Effects of ruxolitinib treatment on metabolic and nutritional parameters in patients with myelofibrosis from COMFORT-I.

Authors:  Ruben A Mesa; Srdan Verstovsek; Vikas Gupta; John O Mascarenhas; Ehab Atallah; Timothy Burn; William Sun; Victor Sandor; Jason Gotlib
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2014-12-27

Review 2.  Cancer cachexia: understanding the molecular basis.

Authors:  Josep M Argilés; Sílvia Busquets; Britta Stemmler; Francisco J López-Soriano
Journal:  Nat Rev Cancer       Date:  2014-10-09       Impact factor: 60.716

3.  A Novel Inflammation and Insulin Resistance Related Indicator to Predict the Survival of Patients With Cancer.

Authors:  Guo-Tian Ruan; Hai-Lun Xie; He-Yang Zhang; Chen-An Liu; Yi-Zhong Ge; Qi Zhang; Zi-Wen Wang; Xi Zhang; Meng Tang; Meng-Meng Song; Xiao-Wei Zhang; Ming Yang; Yong-Bing Chen; Kai-Ying Yu; Li Deng; Yi-Zhen Gong; Wen Hu; Kun-Hua Wang; Ming-Hua Cong; Han-Ping Shi
Journal:  Front Endocrinol (Lausanne)       Date:  2022-06-20       Impact factor: 6.055

4.  Prevention of body weight loss and sarcopenia by a novel selective androgen receptor modulator in cancer cachexia models.

Authors:  Megumi Morimoto; Katsuji Aikawa; Takahito Hara; Masuo Yamaoka
Journal:  Oncol Lett       Date:  2017-10-17       Impact factor: 2.967

Review 5.  Sterile inflammation in Drosophila.

Authors:  Zeeshan Shaukat; Dawei Liu; Stephen Gregory
Journal:  Mediators Inflamm       Date:  2015-04-08       Impact factor: 4.711

6.  Sarcopenia as a prognostic biomarker of advanced urothelial carcinoma.

Authors:  Hiroshi Fukushima; Minato Yokoyama; Yasukazu Nakanishi; Ken-ichi Tobisu; Fumitaka Koga
Journal:  PLoS One       Date:  2015-01-22       Impact factor: 3.240

7.  Cancer cachexia-when proteasomal inhibition is not enough.

Authors:  Jens Fielitz
Journal:  J Cachexia Sarcopenia Muscle       Date:  2016-06-13       Impact factor: 12.910

8.  Nutritional leucine supplementation attenuates cardiac failure in tumour-bearing cachectic animals.

Authors:  Aline Tatiane Toneto; Luiz Alberto Ferreira Ramos; Emilianne Miguel Salomão; Rebeka Tomasin; Miguel Arcanjo Aereas; Maria Cristina Cintra Gomes-Marcondes
Journal:  J Cachexia Sarcopenia Muscle       Date:  2016-02-24       Impact factor: 12.910

Review 9.  Cancer as a Proinflammatory Environment: Metastasis and Cachexia.

Authors:  Nelson Inácio Pinto; June Carnier; Lila M Oyama; Jose Pinhata Otoch; Paulo Sergio Alcântara; Flavio Tokeshi; Claudia M Nascimento
Journal:  Mediators Inflamm       Date:  2015-10-05       Impact factor: 4.711

Review 10.  Potential Biomarkers of Fat Loss as a Feature of Cancer Cachexia.

Authors:  Maryam Ebadi; Vera C Mazurak
Journal:  Mediators Inflamm       Date:  2015-10-05       Impact factor: 4.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.